Status:

UNKNOWN

Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus

Lead Sponsor:

Ruhr University of Bochum

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

35-70 years

Phase:

PHASE4

Brief Summary

An AGE-rich diet can induce after 2-6 weeks persistent increases in mediators linked to vascular dysfunction (e.g. TNFα, VCAM-1) in people with type 2 diabetes mellitus (T2DM). Benfotiamine (BT), the ...

Detailed Description

People with type 2 diabetes mellitus (T2DM) have a two to fivefold increase in cardiovascular mortality compared to non-diabetic controls. Endothelial dysfunction (ED) is an early messenger of athero...

Eligibility Criteria

Inclusion

  • People with type 2 diabetes mellitus
  • Age: 30-70 years

Exclusion

  • History of myocardial infarction, stroke within the previous 6 months
  • Heart failure NYHA III or more
  • Malignant disease
  • Severe diabetes complications
  • Severe hypo- or hypertension
  • Chronic alcohol abuse
  • Renal failure (creatinine \>2mg/dl)

Key Trial Info

Start Date :

September 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2008

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT00446810

Start Date

September 1 2007

End Date

December 1 2008

Last Update

September 27 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Herz- und Diabeteszentrum NRW, Georgstr. 11

Bad Oeynhausen, North Rhine-Westphalia, Germany, 32545